John P. Butler
Immediate Past Chair
John Butler is the Immediate Past Chair of the American Kidney Fund’s Board of Trustees, having served as Chair from 2013 to 2015.
Mr. Butler has more than 25 years of experience leading the development, launch and commercialization of innovative therapies. He joined Akebia Therapeutics as president and CEO in September 2013. He served as CEO of Inspiration Biopharmaceuticals, a company focused on developing products for patients with hemophilia, from 2011 until 2013. He led the sale of the company’s assets, including the company’s lead asset to Baxter Corporation, the world leader in hemophilia. The value of the transactions should total over $1 billion to Inspiration’s shareholders.
From 1997 to 2011, Mr. Butler held various positions at Genzyme Corporation, one of the world’s largest biotechnology companies. While at Genzyme, he most recently served as president of the company’s rare genetic diseases business, which has developed and commercialized first-to-market, transformative therapies for small patient populations. Mr. Butler also led the company’s renal, endocrinology and cardiovascular businesses, growing the division to $1 billion in revenue. Earlier in his career, he held sales and marketing positions at Amgen and Hoffmann-La Roche.
He has spent over 20 years working to improve the lives of patients with kidney disease. He served in a number of commercial roles while at Amgen for Epogen® and he ultimately led the renal business at Genzyme which brought Renagel®, Renvela® and Hectorol® to these patients. He is a member of the board of directors of Relypsa, Inc., a company developing a first-in-class treatment for hyperkalemia in patients with chronic kidney disease.
Mr. Butler received his B.A. in Chemistry from Manhattan College and his M.B.A. from Baruch College.